Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight Report 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor – Pipeline Insight, 2020 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline landscape is provided, which includes the topic overview and Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor mechanism of action.
The assessment part of the report embraces, in-depth Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor pipeline development activities
The report provides insights into:
- All the companies developing therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor with aggregate therapies developed by each company for the same.
- Different therapeutic candidates in early-stage, mid-stage and late stage of development for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.
- Key players involved in Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.
Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Analytical Perspective
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.
Report Highlights
- In the coming years, the Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- There are several companies involved in developing therapies for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor. Launch of emerging therapies of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor will significantly impact the market.
- A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Topics Covered:
1. Report Introduction
2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor
2.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Overview
2.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Classification
2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Structure
2.4. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Mechanism of Action
2.5. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Application
3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor – Analytical Perspective
3.1. In-depth Commercial Assessment
3.1.1. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Acquisition Analysis
4. Therapeutic Assessment
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.3. Assessment by Route of Administration
4.1.4. Assessment by Molecule Type
4.1.5. Assessment by MOA
4.1.6. Assessment by Target
5. Late Stage Products (Phase-III)
6. Mid Stage Products (Phase-II)
7. Early Stage Products (Phase-I)
8. Pre-clinical Products and Discovery Stage Products
9. Inactive Products
10. Dormant Products
11. Discontinued Products
12. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Product Profiles
12.1. Drug Name: Company
12.1.1. Product Description
12.1.2. Research and Development
12.1.3. Product Development Activities
12.1.4. Tabulated Product Summary
13. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Key Companies
14. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Key Products
15. Dormant and Discontinued Products
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation
16. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor – Unmet Needs
17. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor – Future Perspectives
18. Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Analyst Review
19. Appendix
Companies Mentioned
- Abbvie
- Angion Biomedica
- Esai
- Jeil Pharmaceutical
- Jiangxi Qingfeng Pharmaceutical
- Kanion
- Mitsubishi Tanabe Pharma Corporation
- NewGen Therapeutics
- Pfizer
- Sanofi
- Zydus Cadila
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ki8lwc
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
